The University of Chicago Header Logo

Ravi Salgia

TitleEmeritus/Emerita, Professor
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA262292     (WHEELER, DERIC L)Jun 1, 2022 - May 31, 2027
    NIH
    Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
    Role: Co-Principal Investigator

    R01CA247471     (JAIN, MANEESH)Dec 20, 2019 - May 31, 2025
    NIH
    Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer
    Role: Co-Principal Investigator

    R21CA140003     (SALGIA, RAVI)Mar 1, 2009 - Feb 28, 2012
    NIH
    Novel Targeted Therapy in Pancreatic Cancer
    Role: Principal Investigator

    R01CA129501     (SALGIA, RAVI)Jun 2, 2008 - Apr 30, 2014
    NIH
    Role of Paxillin in Lung Cancer
    Role: Principal Investigator

    R01CA125541     (SALGIA, RAVI)Jan 15, 2007 - Nov 30, 2012
    NIH
    Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
    Role: Principal Investigator

    R01CA100750     (SALGIA, RAVI)Apr 1, 2003 - Feb 28, 2013
    NIH
    Role of c-Met in SCLC and Potential for Novel Therapy
    Role: Principal Investigator

    R21CA081324     (ELIAS, ANTHONY D)Apr 5, 1999 - Mar 31, 2003
    NIH
    MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
    Role: Co-Principal Investigator

    R29CA075348     (SALGIA, RAVI)Aug 1, 1997 - Jul 31, 2002
    NIH
    ABNORMALITIES OF MOTILITY OF CML CELLS
    Role: Principal Investigator

    K08CA060821     (SALGIA, RAVI)Aug 15, 1993 - Jul 31, 1996
    NIH
    PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kulkarni P, Salgia R. Comprehending phenotypic plasticity in cancer and evolution. iScience. 2024 Mar 15; 27(3):109308. PMID: 38482503; PMCID: PMC10933540.
      Citations:    
    2. Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, Wheeler DL. Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit. Cancers (Basel). 2024 Jan 11; 16(2). PMID: 38254801; PMCID: PMC10814769.
      Citations:    
    3. Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E, Salgia R, Singhal SS. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023 11; 1878(6):189026. PMID: 37980945.
      Citations:    Fields:    Translation:Humans
    4. Kulkarni P, Mohanty A, Ramisetty S, Duvivier H, Khan A, Shrestha S, Tan T, Merla A, El-Hajjaoui M, Malhotra J, Singhal S, Salgia R. A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11). PMID: 38002269; PMCID: PMC10668935.
      Citations:    Fields:    Translation:Humans
    5. Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, Chou TF, Roy S, Orban J, Kulkarni P, Salgia R. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816. PMID: 37831779; PMCID: PMC10575592.
      Citations: 2     Fields:    Translation:Humans
    6. Ramisetty SK, Garg P, Mohanty A, Mirzapoiazova T, Yue E, Wang E, Horne D, Awasthi S, Kulkarni P, Salgia R, Singhal SS. Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023 11; 217:115847. PMID: 37804871.
      Citations:    Fields:    Translation:HumansCells
    7. Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal SK, Hsu J. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 09 07; 28(9):e748-e755. PMID: 36971500; PMCID: PMC10485287.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    8. Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. JCO Precis Oncol. 2023 Sep; 7:e2200445. PMID: 37656950.
      Citations: 1     Fields:    
    9. Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, Villalona-Calero M, Salgia R, Massarelli E, Lee P, Williams T, Amini A. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 11; 24(7):651-659. PMID: 37714807.
      Citations:    Fields:    Translation:Humans
    10. Boas FE, Salgia R, Waddington T, Massarelli E, Park JJ, Kessler J, Frankel P, Alexander ES, Solomon SB. Phase II Trial of Lung Chemoembolization. J Vasc Interv Radiol. 2023 12; 34(12):2090-2092. PMID: 37611799.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Feng Y, Massarelli E, Forman E, Kovach JS, Salgia R, Synold TW. An LC-MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma. Bioanalysis. 2023 Sep; 15(17):1095-1107. PMID: 37584370; PMCID: PMC10505989.
      Citations:    Fields:    Translation:Humans
    12. Shah A, Chaudhary S, Lakshmanan I, Aithal A, Kisling SG, Sorrell C, Marimuthu S, Gautam SK, Rauth S, Kshirsagar P, Cox JL, Natarajan G, Bhatia R, Mallya K, Rachagani S, Nasser MW, Ganti AK, Salgia R, Kumar S, Jain M, Ponnusamy MP, Batra SK. Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. NPJ Precis Oncol. 2023 Aug 11; 7(1):74. PMID: 37567918; PMCID: PMC10421872.
      Citations: 3     
    13. Fricke J, Wang J, Gallego N, Mambetsariev I, Kim P, Babikian R, Chen BT, Afkhami M, Subbiah V, Salgia R. Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671. PMID: 37580188; PMCID: PMC10840632.
      Citations: 1     Fields:    Translation:Humans
    14. Kulkarni P, Salgia R. On the Virtues of "Team Medicine"-A City of Hope Perspective. J Clin Med. 2023 Jul 26; 12(15). PMID: 37568299; PMCID: PMC10419954.
      Citations:    
    15. Chen BT, Jin T, Ye N, Chen SW, Rockne RC, Yoon S, Mambetsariev I, Daniel E, Salgia R. Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status. Brain Sci. 2023 Jul 11; 13(7). PMID: 37508989; PMCID: PMC10377121.
      Citations:    
    16. Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. iScience. 2023 Aug 18; 26(8):107302. PMID: 37554452; PMCID: PMC10405066.
      Citations: 2     
    17. Mambetsariev I, Fricke J, Gruber SB, Tan T, Babikian R, Kim P, Vishnubhotla P, Chen J, Kulkarni P, Salgia R. Clinical Network Systems Biology: Traversing the Cancer Multiverse. J Clin Med. 2023 Jul 07; 12(13). PMID: 37445570; PMCID: PMC10342467.
      Citations: 1     
    18. Berube LL, Nickel KP, Iida M, Ramisetty S, Kulkarni P, Salgia R, Wheeler DL, Kimple RJ. Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models. Semin Radiat Oncol. 2023 07; 33(3):279-286. PMID: 37331782; PMCID: PMC10287034.
      Citations:    Fields:    Translation:HumansAnimals
    19. Kulkarni P, Salgia R, Rangarajan G. Intrinsically disordered proteins and conformational noise: The hypothesis a decade later. iScience. 2023 Jul 21; 26(7):107109. PMID: 37408690; PMCID: PMC10319216.
      Citations: 4     
    20. Garg P, Awasthi S, Horne D, Salgia R, Singhal SS. The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action. Biochim Biophys Acta Rev Cancer. 2023 07; 1878(4):188929. PMID: 37286146.
      Citations:    Fields:    Translation:HumansAnimals
    21. Singhal SS, Garg R, Mohanty A, Garg P, Ramisetty SK, Mirzapoiazova T, Soldi R, Sharma S, Kulkarni P, Salgia R. Recent Advancement in Breast Cancer Research: Insights from Model Organisms-Mouse Models to Zebrafish. Cancers (Basel). 2023 May 29; 15(11). PMID: 37296923; PMCID: PMC10252042.
      Citations: 2     
    22. Garcia D, Mambetsariev I, Fricke J, Schmolze D, Afkhami M, Mannan R, Kim P, Therese Dingal S, Nguyen B, Babikian R, Fong Y, Salgia R. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023 04; 9(2). PMID: 37160318; PMCID: PMC10240843.
      Citations:    Fields:    Translation:Humans
    23. Sattler M, Salgia R. LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancer. Transl Lung Cancer Res. 2023 Jun 30; 12(6):1350-1354. PMID: 37425423; PMCID: PMC10326781.
      Citations:    
    24. Kostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, Alexandridis R, Yu M, Hong S, Salgia R, Bruce JY, Birge RB, Harari PM, Wheeler DL. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head Neck. 2023 05; 45(5):1255-1271. PMID: 36939040; PMCID: PMC10079616.
      Citations:    Fields:    Translation:AnimalsCells
    25. Zarinshenas R, Amini A, Mambetsariev I, Abuali T, Fricke J, Ladbury C, Salgia R. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers (Basel). 2023 Mar 03; 15(5). PMID: 36900386; PMCID: PMC10000935.
      Citations: 3     
    26. Sattler M, Mambetsariev I, Fricke J, Tan T, Liu S, Vaidehi N, Pisick E, Mirzapoiazova T, Rock AG, Merla A, Sharma S, Salgia R. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. J Clin Med. 2023 Mar 01; 12(5). PMID: 36902723; PMCID: PMC10003860.
      Citations: 2     
    27. Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171. PMID: 36868177.
      Citations: 2     Fields:    Translation:HumansAnimals
    28. Sayer MR, Mambetsariev I, Lu KH, Wong CW, Duche A, Beuttler R, Fricke J, Pharoan R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy. Front Oncol. 2023; 13:1064169. PMID: 36860308; PMCID: PMC9968834.
      Citations: 4     
    29. Presant CA, Ashing K, Raz D, Yeung S, Gascon B, Stewart A, Macalintal J, Sandoval A, Ehrunmwunsee L, Phillips T, Salgia R, Merla A, Subbiah S, El-Hajjouie M, Staley J, Graves H, Pathak R, Dingal S, Sampath S, Laksana B, Joseph T, Eugenio T, Degoma V, Burns K, Phillips S, Tan T, Tarkshian K, Sun V, Amini A, Davy K, Cronkhite J, Cianfrocca M, Brown S, Fong Y, Rosen S. Overcoming Barriers to Tobacco Cessation and Lung Cancer Screening among Racial and Ethnic Minority Groups and Underserved Patients in Academic Centers and Community Network Sites: The City of Hope Experience. J Clin Med. 2023 Feb 06; 12(4). PMID: 36835811; PMCID: PMC9965998.
      Citations:    
    30. Ladbury C, Amini A, Govindarajan A, Mambetsariev I, Raz DJ, Massarelli E, Williams T, Rodin A, Salgia R. Integration of artificial intelligence in lung cancer: Rise of the machine. Cell Rep Med. 2023 02 21; 4(2):100933. PMID: 36738739; PMCID: PMC9975283.
      Citations: 9     Fields:    Translation:Humans
    31. Garg P, Garg R, Horne D, Awasthi S, Salgia R, Singhal SS. Prognostic significance of natural products against multidrug tumor resistance. Cancer Lett. 2023 03 31; 557:216079. PMID: 36736532.
      Citations: 2     Fields:    Translation:Humans
    32. Ladbury C, Abuali T, Liu J, Watkins W, Du D, Massarelli E, Villaflor V, Liu A, Salgia R, Williams T, Glaser S, Amini A. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251. PMID: 36759265.
      Citations:    Fields:    Translation:Humans
    33. Kulkarni P, Wiley HS, Levine H, Sauro H, Anderson A, Wong STC, Meyer AS, Iyengar P, Corlette K, Swanson K, Mohanty A, Bhattacharya S, Patel A, Jain V, Salgia R. Addressing the genetic/nongenetic duality in cancer with systems biology. Trends Cancer. 2023 03; 9(3):185-187. PMID: 36635119.
      Citations: 2     Fields:    Translation:Humans
    34. Ramisetty S, Kulkarni P, Bhattacharya S, Nam A, Singhal SS, Guo L, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Pisick E, Subbiah S, Rajurkar S, Massarelli E, Salgia R, Mohanty A. A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer. J Clin Med. 2023 Jan 11; 12(2). PMID: 36675528.
      Citations: 6     
    35. Khan P, Siddiqui JA, Kshirsagar PG, Venkata RC, Maurya SK, Mirzapoiazova T, Perumal N, Chaudhary S, Kanchan RK, Fatima M, Khan MA, Rehman AU, Lakshmanan I, Mahapatra S, Talmon GA, Kulkarni P, Ganti AK, Jain M, Salgia R, Batra SK, Nasser MW. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1. PMID: 36597126; PMCID: PMC9811802.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    36. Wing SE, Jankowska MM, Zou X, Sosa E, Yang JA, Benmarhnia T, Neuhausen SL, Nelson R, Salgia R, Gray SW, Erhunmwunsee L. Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240. PMID: 36383274; PMCID: PMC10322188.
      Citations: 1     Fields:    Translation:Humans
    37. Bosserman LD, Mambetsariev I, Ladbury C, Barzi A, Johnson D, Morse D, Deaville D, Smith W, Rajurkar S, Merla A, Hajjar G, Kim D, Fricke J, Trisal V, Salgia R. Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans. J Clin Med. 2022 Nov 14; 11(22). PMID: 36431215.
      Citations: 4     
    38. Sattler M, Salgia R. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131. PMID: 36331252.
      Citations:    Fields:    Translation:Humans
    39. Sattler M, Mohanty A, Kulkarni P, Salgia R. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023 01; 9(1):42-54. PMID: 36751115.
      Citations: 9     Fields:    Translation:Humans
    40. Presant CA, Ashing K, Yeung S, Macalintal J, Tiep B, Sandoval A, Brown S, Cianfrocca M, Erhunmwunsee L, Raz D, Amini A, Salgia R, Fu P, Merla A, Graves H, Pathak R, Dingal S, Tan T, Tarkeshian K, Nikolaenko L, Burns K, Sampath S, Laksana B, Gascon B, Tainatongo-Landin D, Degoma V, Subbiah S, Rai R, Rosen S. Increasing clinician participation in tobacco cessation by an implementation science-based tobacco cessation champion program. Cancer Causes Control. 2023 Jan; 34(1):81-88. PMID: 36224501; PMCID: PMC9555700.
      Citations: 1     Fields:    Translation:Humans
    41. Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2022 Oct 08; 14(19). PMID: 36230855; PMCID: PMC9562655.
      Citations: 4     
    42. Ladbury C, Zarinshenas R, Semwal H, Tam A, Vaidehi N, Rodin AS, Liu A, Glaser S, Salgia R, Amini A. Utilization of model-agnostic explainable artificial intelligence frameworks in oncology: a narrative review. Transl Cancer Res. 2022 Oct; 11(10):3853-3868. PMID: 36388027; PMCID: PMC9641128.
      Citations: 8     
    43. Kulkarni P, Mohanty A, Bhattacharya S, Singhal S, Guo L, Ramisetty S, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Gupta N, Kim P, Babikian R, Rajurkar S, Subbiah S, Tan T, Nguyen D, Merla A, Kollimuttathuillam SV, Phillips T, Baik P, Tan B, Vashi P, Shrestha S, Leach B, Garg R, Rich PL, Stewart FM, Pisick E, Salgia R. Addressing Drug Resistance in Cancer: A Team Medicine Approach. J Clin Med. 2022 Sep 27; 11(19). PMID: 36233569; PMCID: PMC9572909.
      Citations: 4     
    44. Singhal SS, Garg R, Horne D, Singhal S, Awasthi S, Salgia R. RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. Biochim Biophys Acta Rev Cancer. 2022 09; 1877(5):188803. PMID: 36150564.
      Citations: 1     Fields:    Translation:HumansAnimals
    45. Novak J, Salgia R, West H, Villalona-Calero MA, Sampath S, Williams T, Villaflor V, Massarelli E, Pathak R, Koczywas M, Chau B, Amini A. Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC. Cancers (Basel). 2022 Aug 18; 14(16). PMID: 36010982; PMCID: PMC9406789.
      Citations: 2     
    46. Kulkarni P, Mohanty A, Salgia R, Uversky VN. Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning system. Int J Biol Macromol. 2022 Oct 31; 219:366-373. PMID: 35931296.
      Citations: 3     Fields:    Translation:Animals
    47. Liu J, Govindarajan A, Williams TM, Kim J, Erhunmwunsee L, Raz D, Massarelli E, Salgia R, Chen YJ, Amini A. An Updated Review on Radiation Treatment Management in Thymus Cancers. Clin Lung Cancer. 2022 Nov; 23(7):561-570. PMID: 35941046.
      Citations: 2     Fields:    Translation:Humans
    48. Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022 11; 86(Pt 2):233-246. PMID: 35787939.
      Citations: 11     Fields:    Translation:Humans
    49. Kulkarni P, Salgia R, Uversky VN. Intrinsic disorder, extraterrestrial peptides, and prebiotic life on the earth. J Biomol Struct Dyn. 2023 Jul-Aug; 41(12):5481-5485. PMID: 35723592.
      Citations: 1     Fields:    
    50. Gautam SK, Dalal V, Sajja BR, Gupta S, Gulati M, Dwivedi NV, Aithal A, Cox JL, Rachagani S, Liu Y, Chung V, Salgia R, Batra SK, Jain M. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Cancer Lett. 2022 09 28; 544:215801. PMID: 35732216; PMCID: PMC10198578.
      Citations: 1     Fields:    Translation:Humans
    51. French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI, Lauer UM, Massard C. Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505. PMID: 35417004; PMCID: PMC9197941.
      Citations: 15     Fields:    Translation:Humans
    52. Zarinshenas R, Ladbury C, McGee H, Raz D, Erhunmwunsee L, Pathak R, Glaser S, Salgia R, Williams T, Amini A. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022 08; 173:10-18. PMID: 35618098.
      Citations: 5     Fields:    Translation:Humans
    53. Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447. PMID: 35461210; PMCID: PMC9035247.
      Citations: 3     Fields:    Translation:HumansCells
    54. Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R, Tissot FLH. Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2022 Apr 01; 21(4):700. PMID: 35373301; PMCID: PMC10996841.
      Citations:    Fields:    
    55. Kulkarni P, Leite VBP, Roy S, Bhattacharyya S, Mohanty A, Achuthan S, Singh D, Appadurai R, Rangarajan G, Weninger K, Orban J, Srivastava A, Jolly MK, Onuchic JN, Uversky VN, Salgia R. Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma. Biophys Rev (Melville). 2022 Mar; 3(1):011306. PMID: 38505224; PMCID: PMC10903413.
      Citations: 1     
    56. Mambetsariev I, Arvanitis L, Fricke J, Pharaon R, Baroz AR, Afkhami M, Koczywas M, Massarelli E, Salgia R. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Med. 2022 Mar 05; 11(5). PMID: 35268520; PMCID: PMC8911080.
      Citations: 9     
    57. Kulkarni P, Bhattacharya S, Achuthan S, Behal A, Jolly MK, Kotnala S, Mohanty A, Rangarajan G, Salgia R, Uversky V. Intrinsically Disordered Proteins: Critical Components of the Wetware. Chem Rev. 2022 03 23; 122(6):6614-6633. PMID: 35170314; PMCID: PMC9250291.
      Citations: 15     Fields:    Translation:Cells
    58. Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS. Correction: 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget. 2022; 13:331. PMID: 35261722; PMCID: PMC8896966.
      Citations:    Fields:    
    59. Liu J, Ladbury C, Kim J, Raz D, Erhunmwunsee L, West HJ, Williams T, Salgia R, Massarelli E, Amini A. Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. J Thorac Oncol. 2022 02; 17(2):194-196. PMID: 35074226.
      Citations: 4     Fields:    Translation:Humans
    60. Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54. PMID: 34991107.
      Citations: 1     Fields:    Translation:Humans
    61. Lapidot M, Saladi SV, Salgia R, Sattler M. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Front Pharmacol. 2021; 12:806570. PMID: 35069219; PMCID: PMC8776703.
      Citations: 2     
    62. Kulkarni P, Behal A, Mohanty A, Salgia R, Nedelcu AM, Uversky VN. Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity. Int J Biol Macromol. 2022 Mar 15; 201:29-36. PMID: 34998872.
      Citations: 2     Fields:    Translation:Animals
    63. Salgia R. The next targets for small cell lung cancer. Clin Adv Hematol Oncol. 2022 01; 20(1):35-36. PMID: 35060960.
      Citations:    Fields:    Translation:Humans
    64. Achuthan S, Chatterjee R, Kotnala S, Mohanty A, Bhattacharya S, Salgia R, Kulkarni P. Leveraging deep learning algorithms for synthetic data generation to design and analyze biological networks. J Biosci. 2022; 47. PMID: 36222162.
      Citations: 4     Fields:    Translation:Humans
    65. Nam A, Mohanty A, Bhattacharya S, Kotnala S, Achuthan S, Hari K, Srivastava S, Guo L, Nathan A, Chatterjee R, Jain M, Nasser MW, Batra SK, Rangarajan G, Massarelli E, Levine H, Jolly MK, Kulkarni P, Salgia R. Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules. 2021 12 21; 12(1). PMID: 35053156; PMCID: PMC8773639.
      Citations: 9     Fields:    Translation:Humans
    66. Ross JA, Komoda K, Pal S, Dickter J, Salgia R, Dadwal S. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27. PMID: 34873868; PMCID: PMC8704147.
      Citations: 8     Fields:    Translation:Humans
    67. Kulkarni P, Achuthan S, Bhattacharya S, Jolly MK, Kotnala S, Mohanty A, Orban J, Roy S, Rangarajan G, Salgia R, Leite VBP. Protein conformational dynamics and phenotypic switching. Biophys Rev. 2021 Dec; 13(6):1127-1138. PMID: 35059032; PMCID: PMC8724335.
      Citations: 4     
    68. Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Retraction. Sci Signal. 2021 Nov 09; 14(708):eabn0168. PMID: 34752142; PMCID: PMC8787917.
      Citations:    Fields:    
    69. Salgia SK, Govindarajan A, Salgia R, Pal SK. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? JCO Precis Oncol. 2021 11; 5:767-770. PMID: 34994610.
      Citations: 4     Fields:    Translation:Humans
    70. Du D, Abuali T, Ladbury CJ, Liu JR, Liu A, Watkins WT, Massarelli E, Villaflor VM, Salgia R, Williams TM, Glaser SM, Amini A. Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e427. PMID: 34701427.
      Citations:    
    71. Roosan MR, Mambetsariev I, Salgia R. Response. Chest. 2021 10; 160(4):e375-e376. PMID: 34625192.
      Citations:    Fields:    
    72. Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist. 2021 12; 26(12):1052-1061. PMID: 34378270; PMCID: PMC8649039.
      Citations: 22     Fields:    Translation:Humans
    73. Yue E, Yang G, Yao Y, Wang G, Mohanty A, Fan F, Zhao L, Zhang Y, Mirzapoiazova T, Walser TC, Rodriguez-Rodriguez L, Fong Y, Salgia R, Wang EW. Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment. Cancers (Basel). 2021 Aug 24; 13(17). PMID: 34503075; PMCID: PMC8428227.
      Citations: 4     
    74. Pathak R, Salgia R. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139. PMID: 34419376.
      Citations: 1     Fields:    Translation:Humans
    75. Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R, Tissot FLH. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835. PMID: 34253596; PMCID: PMC8722383.
      Citations: 8     Fields:    Translation:HumansCells
    76. Baroz AR, Mambetsariev I, Fricke J, Pharaon R, Tan T, Kidambi T, Sandhu KS, Koczywas M, Salgia R. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus. 2021 Jul; 13(7):e16266. PMID: 34377604; PMCID: PMC8349225.
      Citations: 3     
    77. Pathak R, Amini A, Hill A, Massarelli E, Salgia R. Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. Cancers (Basel). 2021 Jul 07; 13(14). PMID: 34298620; PMCID: PMC8303291.
      Citations: 5     
    78. Salgia S, Salgia N, Prajapati S, Seghal I, Bautista F, Ruel N, Salgia M, Salgia DA, Salgia R, Pal SK. Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. Kidney Cancer. 2021; 5(2):73-78. PMID: 34368520; PMCID: PMC8341455.
      Citations:    
    79. Singhal SS, Srivastava S, Mirzapoiazova T, Horne D, Awasthi S, Salgia R. Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Lett. 2021 10 10; 518:10-22. PMID: 34126193.
      Citations: 3     Fields:    Translation:HumansAnimals
    80. Erhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, Koczywas M, Massarelli E, West HL, Reckamp KL, Kittles RA, Salgia R, Seewaldt VL, Neuhausen SL, Gray SW. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505. PMID: 34088750; PMCID: PMC8338883.
      Citations: 5     Fields:    Translation:Humans
    81. Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, Frank DA, Salgia R, Griffin JD, Saladi SV, Bueno R, Sattler M. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592. PMID: 34088988; PMCID: PMC8368004.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    82. Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel). 2021 Jun 03; 13(11). PMID: 34204917; PMCID: PMC8199748.
      Citations: 8     
    83. Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel). 2021 May 28; 13(11). PMID: 34071259; PMCID: PMC8198372.
      Citations: 1     
    84. Singhal SS, Mohanty A, Kulkarni P, Horne D, Awasthi S, Salgia R. RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. Carcinogenesis. 2021 05 28; 42(5):742-752. PMID: 33623991; PMCID: PMC8599733.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    85. Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039. PMID: 34031395; PMCID: PMC8144406.
      Citations: 16     Fields:    Translation:HumansCells
    86. Khan P, Ebenezer NS, Siddiqui JA, Maurya SK, Lakshmanan I, Salgia R, Batra SK, Nasser MW. MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022 04; 124:114-126. PMID: 34034986; PMCID: PMC8606619.
      Citations: 7     Fields:    Translation:Humans
    87. Soldi R, Halder TG, Sampson S, Vankayalapati H, Weston A, Thode T, Bhalla KN, Ng S, Rodriguez Del Villar R, Drenner K, Kaadige MR, Horrigan SK, Batra SK, Salgia R, Sharma S. The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin ß-Like 1-ß-Catenin Protein Complex. J Pharmacol Exp Ther. 2021 08; 378(2):77-86. PMID: 34006586.
      Citations: 5     Fields:    Translation:Humans
    88. Lakshmanan I, Chaudhary S, Vengoji R, Seshacharyulu P, Rachagani S, Carmicheal J, Jahan R, Atri P, Chirravuri-Venkata R, Gupta R, Marimuthu S, Perumal N, Rauth S, Kaur S, Mallya K, Smith LM, Lele SM, Ponnusamy MP, Nasser MW, Salgia R, Batra SK, Ganti AK. ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Mol Oncol. 2021 07; 15(7):1866-1881. PMID: 33792183; PMCID: PMC8253099.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    89. Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107. PMID: 33878340; PMCID: PMC8449001.
      Citations: 13     Fields:    Translation:Humans
    90. Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, Sand SR, Mejia RM, Tsou TC, Salgia R, Weitzel JN. Germline mutations and age at onset of lung adenocarcinoma. Cancer. 2021 08 01; 127(15):2801-2806. PMID: 33858029; PMCID: PMC8794435.
      Citations: 9     Fields:    Translation:Humans
    91. Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54. PMID: 33740988; PMCID: PMC7977189.
      Citations: 29     Fields:    Translation:HumansAnimals
    92. Chau B, Ituarte PH, Shinde A, Li R, Vazquez J, Glaser S, Massarelli E, Salgia R, Erhunmwunsee L, Ashing K, Amini A. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667. PMID: 33734614; PMCID: PMC8026917.
      Citations: 2     Fields:    Translation:Humans
    93. Salgia R, Boehmer LM, Celestin C, Yu H, Spigel DR. Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. JCO Oncol Pract. 2021 08; 17(8):e1120-e1130. PMID: 33689449.
      Citations: 5     Fields:    Translation:Humans
    94. Chen BT, Jin T, Ye N, Mambetsariev I, Wang T, Wong CW, Chen Z, Rockne RC, Colen RR, Holodny AI, Sampath S, Salgia R. Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. Front Oncol. 2021; 11:621088. PMID: 33747933; PMCID: PMC7973105.
      Citations: 18     
    95. Salgia R, Kulkarni P, Levine H, Loughlin DT. Quantifying Cancer: More Than Just a Numbers Game. Trends Cancer. 2021 04; 7(4):267-269. PMID: 33648875.
      Citations: 2     Fields:    Translation:Humans
    96. Bhattacharya S, Mohanty A, Achuthan S, Kotnala S, Jolly MK, Kulkarni P, Salgia R. Group Behavior and Emergence of Cancer Drug Resistance. Trends Cancer. 2021 04; 7(4):323-334. PMID: 33622644; PMCID: PMC8500356.
      Citations: 12     Fields:    Translation:HumansAnimals
    97. Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, Wakelee HA. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041. PMID: 33588109.
      Citations: 30     Fields:    Translation:Humans
    98. Singhal J, Chikara S, Horne D, Awasthi S, Salgia R, Singhal SS. Targeting RLIP with CRISPR/Cas9 controls tumor growth. Carcinogenesis. 2021 Feb 11; 42(1):48-57. PMID: 32426802; PMCID: PMC7877558.
      Citations: 9     Fields:    Translation:HumansCells
    99. Singhal J, Kulkarni P, Horne D, Awasthi S, Salgia R, Singhal SS. Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Mol Carcinog. 2021 03; 60(3):213-223. PMID: 33544936; PMCID: PMC7952002.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    100. Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R. Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clin Lung Cancer. 2021 09; 22(5):e703-e707. PMID: 33640299; PMCID: PMC8978804.
      Citations: 4     Fields:    Translation:Humans
    101. Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186. PMID: 33521700; PMCID: PMC7817862.
      Citations: 47     Fields:    Translation:HumansCells
    102. Liu J, Hui C, Ladbury C, Waddington T, Erhunmwunsee L, Raz D, Kim J, Salgia R, Chenery S, Pearlstein D, Schwer A, Amini A. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clin Lung Cancer. 2021 09; 22(5):e678-e683. PMID: 33712362.
      Citations: 1     Fields:    Translation:Humans
    103. Singhal SS, Horne D, Singhal J, Awasthi S, Salgia R. Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512. PMID: 33460725; PMCID: PMC9082734.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    104. Bosserman LD, Cianfrocca M, Yuh B, Yeon C, Chen H, Sentovich S, Polverini A, Zachariah F, Deaville D, Lee AB, Sedrak MS, King E, Gray S, Morse D, Glaser S, Bhatt G, Adeimy C, Tan T, Chao J, Nam A, Paz IB, Kruper L, Rao P, Sokolov K, Kulkarni P, Salgia R, Yamzon J, Johnson D. Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. J Clin Med. 2021 Jan 07; 10(2). PMID: 33430334; PMCID: PMC7825796.
      Citations: 10     
    105. Lapidot M, Case AE, Larios D, Gandler HI, Meng C, Weisberg EL, Poitras MJ, Gokhale PC, Paweletz CP, Podar K, Salgia R, Saladi SV, Griffin JD, Frank DA, Bueno R, Sattler M, Tošic I. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1). PMID: 33374980; PMCID: PMC7792575.
      Citations: 9     
    106. Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers (Basel). 2020 Dec 20; 12(12). PMID: 33419311; PMCID: PMC7767234.
      Citations: 12     
    107. Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6). PMID: 33335011; PMCID: PMC7784494.
      Citations: 4     Fields:    Translation:Humans
    108. Ebelt ND, Zuniga E, Marzagalli M, Zamloot V, Blazar BR, Salgia R, Manuel ER. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines. 2020 Dec 16; 8(12). PMID: 33339195; PMCID: PMC7765568.
      Citations: 6     
    109. Ando K, Ozonoff A, Lee SY, Voisine M, Parker JT, Nakanishi R, Nishimura S, Yang J, Grace Z, Tran B, Diefenbach TJ, Maehara Y, Yasui H, Irino T, Salgia R, Terashima M, Gibbs P, Ramanathan RK, Oki E, Mori M, Kulke M, Hartshorn K, Bharti A. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clin Colorectal Cancer. 2021 06; 20(2):e129-e138. PMID: 33731288.
      Citations: 1     Fields:    Translation:Humans
    110. Reckamp KL, McQuerry JA, Mambetsariev I, Pharaon R, Yost SE, Fricke J, Mirzapoiazova T, Pillai RK, Khan Z, Fakih M, Yuan Y, Koczywas M, Massarelli E, Kulkarni P, Pal SK, Sattler M, Bild A, Salgia R. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Sci OA. 2020 Nov 25; 7(2):FSO662. PMID: 33437521; PMCID: PMC7787173.
      Citations: 1     
    111. Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, Salgia R, Batra SK, Nasser MW. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 2022 08; 83:57-76. PMID: 33220460; PMCID: PMC8218609.
      Citations: 17     Fields:    Translation:HumansCells
    112. Fricke J, Mambetsariev I, Pharaon R, Subbiah S, Rajurkar S, Salgia R. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report. Medicine (Baltimore). 2020 Nov 13; 99(46):e22323. PMID: 33181636; PMCID: PMC7668523.
      Citations: 8     Fields:    Translation:Humans
    113. Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Arvanitis LD, Nasser MW, Batra SK, Orban J, Jolly MK, Massarelli E, Kulkarni P, Salgia R. Erratum: A Non-genetic Mechanism Involving the Integrin ß4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. iScience. 2020 Nov 20; 23(11):101679. PMID: 33134900; PMCID: PMC7588857.
      Citations: 2     
    114. Srivastava S, Pang KM, Iida M, Nelson MS, Liu J, Nam A, Wang J, Mambetsariev I, Pillai R, Mohanty A, McDaniel N, Behal A, Kulkarni P, Wheeler DL, Salgia R. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. iScience. 2020 Nov 20; 23(11):101692. PMID: 33196021; PMCID: PMC7644594.
      Citations: 6     
    115. Brahmer JR, Johnson ML, Viteri S, Sarto JC, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou VA, Rajan A, Bandyopadhyay N, Allred AJ, Wade M, Mason GE, Zudaire E, Knoblauch RE, Stone N, Lorenzi MV, Hassan R, Cobo M. JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clin Res Rep. 2021 Feb; 2(2):100103. PMID: 34589981; PMCID: PMC8474274.
      Citations: 9     
    116. Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97. PMID: 33039348.
      Citations: 10     Fields:    Translation:Humans
    117. Salgia R, Kulkarni P. Integrating Clinical and Translational Research Networks-Building Team Medicine. J Clin Med. 2020 Sep 15; 9(9). PMID: 32942638; PMCID: PMC7563426.
      Citations: 5     
    118. Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis. 2020 Sep; 12(9):5086-5095. PMID: 33145085; PMCID: PMC7578487.
      Citations: 21     
    119. Pharaon R, Mambetsariev I, Fricke J, Salgia R. Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. J Thorac Dis. 2020 Sep; 12(9):5096-5103. PMID: 33145086; PMCID: PMC7578509.
      Citations:    
    120. Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Nasser MW, Batra SK, Jolly MK, Massarelli E, Kulkarni P, Orban J, Salgia R. A Non-genetic Mechanism Involving the Integrin ß4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. iScience. 2020 Sep 25; 23(9):101496. PMID: 32947124; PMCID: PMC7502350.
      Citations: 17     
    121. Huang LS, Kotha SR, Avasarala S, VanScoyk M, Winn RA, Pennathur A, Yashaswini PS, Bandela M, Salgia R, Tyurina YY, Kagan VE, Zhu X, Reddy SP, Sudhadevi T, Punathil-Kannan PK, Harijith A, Ramchandran R, Bikkavilli RK, Natarajan V. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem. 2020 09 18; 295(38):13393-13406. PMID: 32732285; PMCID: PMC7504921.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    122. Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R. Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. J Clin Med. 2020 Jul 30; 9(8). PMID: 32751469; PMCID: PMC7464169.
      Citations: 5     
    123. Amanam I, Mambetsariev I, Gupta R, Salgia R. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? JCO Oncol Pract. 2021 01; 17(1):52-53. PMID: 32644904.
      Citations:    Fields:    Translation:Humans
    124. Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Hozo I, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract. 2021 02; 17(2):e257-e265. PMID: 32639928; PMCID: PMC8258019.
      Citations: 7     Fields:    Translation:Humans
    125. Malik R, Mambetsariev I, Fricke J, Chawla N, Nam A, Pharaon R, Salgia R. MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301. PMID: 32593403.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    126. Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, Baroz A, Fricke J, Pharaon R, Romo H, Waddington T, Babikian R, Buck L, Kulkarni P, Cianfrocca M, Djulbegovic B, Pal SK. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. J Clin Med. 2020 Jun 16; 9(6). PMID: 32560187; PMCID: PMC7356888.
      Citations: 4     
    127. Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med. 2020 Jun 15; 9(6). PMID: 32549358; PMCID: PMC7356243.
      Citations: 8     
    128. Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Li W, Shen C, Sun J, Kulkarni P, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen MJ, Marcucci G, Salgia R, Li L, Fathi AT, Li Z, Mulloy JC, Wei M, Horne D, Chen J, Müschen M. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020 07 13; 38(1):79-96.e11. PMID: 32531268; PMCID: PMC7363590.
      Citations: 250     Fields:    Translation:HumansCells
    129. Presant CA, Salgia R, Kulkarni P, Tiep BL, Sanani S, Leach B, Ashing K, Sandoval J, Sedrak MS, Landau S, Yeung S, Raz D, Subbiah S. Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. J Clin Med. 2020 Jun 11; 9(6). PMID: 32545244; PMCID: PMC7356827.
      Citations: 5     
    130. Galvez C, Jacob S, Finkelman BS, Zhao J, Tegtmeyer K, Chae YK, Mohindra N, Salgia R, Jovanovic B, Behdad A, Villaflor V. The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget. 2020 May 26; 11(21):1953-1960. PMID: 32523650; PMCID: PMC7260116.
      Citations: 11     Fields:    
    131. Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee PP, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181. PMID: 32554069; PMCID: PMC8158847.
      Citations: 5     Fields:    Translation:Humans
    132. McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, Salgia R, Hong S, Bruce JY, Kimple RJ, Wheeler DL. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359. PMID: 32439698; PMCID: PMC7442604.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    133. Jana S, Krishna M, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28. PMID: 32387443.
      Citations: 6     Fields:    Translation:HumansCells
    134. Chen BT, Chen Z, Ye N, Mambetsariev I, Fricke J, Daniel E, Wang G, Wong CW, Rockne RC, Colen RR, Nasser MW, Batra SK, Holodny AI, Sampath S, Salgia R. Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. Front Oncol. 2020; 10:593. PMID: 32391274; PMCID: PMC7188953.
      Citations: 17     
    135. Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022. PMID: 32334240.
      Citations: 34     Fields:    Translation:HumansAnimals
    136. Mirzapoiazova T, Pozhitkov A, Nam A, Mambetsariev I, Nelson MS, Tan YC, Zhang K, Raz D, Singhal S, Nasser MW, Kulkarni P, Batra SK, Sattler M, Salgia R. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. Int J Oncol. 2020 07; 57(1):80-86. PMID: 32236606; PMCID: PMC7252467.
      Citations: 1     Fields:    Translation:HumansCells
    137. Chen BT, Jin T, Ye N, Mambetsariev I, Daniel E, Wang T, Wong CW, Rockne RC, Colen R, Holodny AI, Sampath S, Salgia R. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56. PMID: 32179095; PMCID: PMC7237274.
      Citations: 21     Fields:    Translation:Humans
    138. Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217. PMID: 32127466.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    139. Krishna BM, Jana S, Panda AK, Horne D, Awasthi S, Salgia R, Singhal SS. Association of TGF-ß1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies †. Cancers (Basel). 2020 Feb 18; 12(2). PMID: 32085560; PMCID: PMC7072663.
      Citations: 1     
    140. Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, Sampath S, Vora L, Qiu F, Smith L, Batra SK, Massarelli E, Koczywas M, Reckamp K, Salgia R. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188. PMID: 32045431; PMCID: PMC7012442.
      Citations: 6     Fields:    Translation:Humans
    141. Carmicheal J, Atri P, Sharma S, Kumar S, Chirravuri Venkata R, Kulkarni P, Salgia R, Ghersi D, Kaur S, Batra SK. Presence and structure-activity relationship of intrinsically disordered regions across mucins. FASEB J. 2020 02; 34(2):1939-1957. PMID: 31908009; PMCID: PMC7018569.
      Citations: 3     Fields:    Translation:HumansCells
    142. Jana S, Madhu Krishna B, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020 04; 174:113789. PMID: 31911091; PMCID: PMC9048250.
      Citations: 36     Fields:    Translation:HumansCells
    143. Singhal SS, Salgia R, Verma N, Horne D, Awasthi S. RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochim Biophys Acta Rev Cancer. 2020 01; 1873(1):188337. PMID: 31904398.
      Citations: 6     Fields:    Translation:HumansCells
    144. Zhang K, Yang L, Wang J, Sun T, Guo Y, Nelson R, Tong TR, Pangeni R, Salgia R, Raz DJ. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167. PMID: 31842906; PMCID: PMC6916027.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    145. Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301. PMID: 31778074.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    146. Griffiths JI, Cohen AL, Jones V, Salgia R, Chang JT, Bild AH. Opportunities for improving cancer treatment using systems biology. Curr Opin Syst Biol. 2019 Oct; 17:41-50. PMID: 32518857; PMCID: PMC7282416.
      Citations: 3     
    147. Nardi IK, Stark JM, Larsen A, Salgia R, Raz DJ. USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. Mol Cancer Res. 2020 03; 18(3):424-435. PMID: 31685642; PMCID: PMC9285637.
      Citations: 8     Fields:    Translation:Humans
    148. Mirzapoiazova T, Li H, Nathan A, Srivstava S, Nasser MW, Lennon F, Armstrong B, Mambetsariev I, Chu PG, Achuthan S, Batra SK, Kulkarni P, Salgia R. Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. J Clin Med. 2019 Oct 18; 8(10). PMID: 31635288; PMCID: PMC6832496.
      Citations: 1     
    149. Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, Jolly MK, Kulkarni P, Salgia R. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. J Clin Med. 2019 Oct 18; 8(10). PMID: 31635338; PMCID: PMC6832522.
      Citations: 17     
    150. Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 2019 Sep 04; 8(9):49. PMID: 31484920; PMCID: PMC6726628.
      Citations: 14     
    151. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731. PMID: 31470129.
      Citations: 4     Fields:    Translation:Humans
    152. Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R. The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. Bioinformatics. 2019 08 15; 35(16):2738-2748. PMID: 30615123; PMCID: PMC6691335.
      Citations: 2     Fields:    Translation:Humans
    153. Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett. 2019 10 01; 461:123-131. PMID: 31326555; PMCID: PMC9003668.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    154. Roth KG, Mambetsariev I, Kulkarni P, Salgia R. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends Mol Med. 2020 01; 26(1):119-134. PMID: 31327706; PMCID: PMC6938552.
      Citations: 73     Fields:    Translation:HumansAnimalsCells
    155. Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R. Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. J Clin Med. 2019 Jul 16; 8(7). PMID: 31315252; PMCID: PMC6679065.
      Citations: 2     
    156. House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR, Ramírez J. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640. PMID: 31274208.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    157. Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717. PMID: 31260832.
      Citations: 2     Fields:    Translation:Humans
    158. Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143. PMID: 31200820.
      Citations: 13     Fields:    Translation:Humans
    159. Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S. Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Mol Carcinog. 2019 08; 58(8):1438-1449. PMID: 31006917; PMCID: PMC8742507.
      Citations: 9     Fields:    Translation:Animals
    160. Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019 Aug; 58(8):1095-1101. PMID: 30958075.
      Citations: 4     Fields:    Translation:Humans
    161. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Mol Cancer Ther. 2019 Apr; 18(4):868. PMID: 30936412.
      Citations:    Fields:    
    162. Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344. PMID: 30741758; PMCID: PMC7597761.
      Citations: 5     Fields:    Translation:Humans
    163. Wang C, Kulkarni P, Salgia R. Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Mol Ther Oncolytics. 2019 Jun 28; 13:1-6. PMID: 30976658; PMCID: PMC6444295.
      Citations: 16     
    164. Gong J, Placencio-Hickok V, Guan M, Hendifar A, Salgia R, Chehrazi-Raffle A. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med. 2019 Mar 18; 8(1):9. PMID: 30887236; PMCID: PMC6423251.
      Citations: 43     Fields:    
    165. Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Levine H, Wolynes PG, Salgia R, Rangarajan G, Uversky V, Orban J, Jolly MK, Onuchic JN. Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. Biomolecules. 2019 02 22; 9(2). PMID: 30813315; PMCID: PMC6406393.
      Citations: 12     Fields:    Translation:HumansCells
    166. Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S. RLIP: An existential requirement for breast carcinogenesis. Biochim Biophys Acta Rev Cancer. 2019 04; 1871(2):281-288. PMID: 30771458.
      Citations: 6     Fields:    Translation:HumansAnimals
    167. Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. RLIP inhibition suppresses breast-to-lung metastasis. Cancer Lett. 2019 04 10; 447:24-32. PMID: 30684594; PMCID: PMC8806386.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    168. Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43. PMID: 31209840.
      Citations: 11     Fields:    Translation:Humans
    169. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2018 Dec 01; 24(23):6099. PMID: 30510088.
      Citations:    Fields:    
    170. Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biol Ther. 2018; 19(11):1023-1032. PMID: 30311833; PMCID: PMC6301806.
      Citations: 5     Fields:    
    171. Gong J, Hendifar A, Tuli R, Cho M, Chung V, Li D, Salgia R, Chuang J. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018 Oct 08; 7(1):32. PMID: 30294755; PMCID: PMC6174117.
      Citations: 15     Fields:    
    172. Wood K, Byron E, Janisch L, Salgia R, Sharma MR. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol. 2018 10; 41(10):963-966. PMID: 28654574; PMCID: PMC5743778.
      Citations: 1     Fields:    Translation:Humans
    173. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667. PMID: 30266660.
      Citations: 40     Fields:    Translation:Humans
    174. Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. J Proteomics. 2019 02 10; 192:233-245. PMID: 30248461; PMCID: PMC8817450.
      Citations: 2     Fields:    Translation:HumansCells
    175. Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Mol Carcinog. 2018 12; 57(12):1751-1762. PMID: 30136444; PMCID: PMC8829755.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    176. Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS. Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Lett. 2018 12 01; 438:144-153. PMID: 30223070; PMCID: PMC8824581.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    177. Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. J Oncol Pract. 2018 09; 14(9):569-571. PMID: 30044685.
      Citations: 4     Fields:    Translation:Humans
    178. Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Heuristic value-based framework for lung cancer decision-making. Oncotarget. 2018 Jul 06; 9(52):29877-29891. PMID: 30042820; PMCID: PMC6057456.
      Citations: 3     Fields:    
    179. Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 07; 74(1):124-128. PMID: 29685646.
      Citations: 27     Fields:    Translation:Humans
    180. Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018 08; 45(4):210-219. PMID: 30286944.
      Citations: 21     Fields:    Translation:Humans
    181. Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P. Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. J Clin Med. 2018 Jun 17; 7(6). PMID: 29914187; PMCID: PMC6025510.
      Citations: 8     
    182. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 10     Fields:    Translation:HumansCells
    183. Gong J, Salgia R. Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018 06; 14(6):359-366. PMID: 29894664; PMCID: PMC6002253.
      Citations: 26     Fields:    Translation:Humans
    184. Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M. Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget. 2018 May 25; 9(40):26226-26242. PMID: 29899855; PMCID: PMC5995226.
      Citations: 10     Fields:    
    185. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103. PMID: 29730462.
      Citations: 11     Fields:    Translation:Humans
    186. Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 2018 Apr 13; 9(28):19793-19806. PMID: 29731983; PMCID: PMC5929426.
      Citations: 23     Fields:    
    187. Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget. 2018 Apr 06; 9(26):18053-18068. PMID: 29719590; PMCID: PMC5915057.
      Citations: 13     Fields:    
    188. Mambetsariev I, Vora L, Yu KW, Salgia R. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314. PMID: 29562902; PMCID: PMC5863467.
      Citations: 3     Fields:    Translation:Humans
    189. Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Ernst T, Hochhaus A, Müschen M. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018 04 05; 173(2):470-484.e18. PMID: 29551267; PMCID: PMC6284818.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    190. Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327. PMID: 29303405; PMCID: PMC5902231.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    191. Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908. PMID: 29451020.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    192. Salgia R, Kulkarni P. The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer. 2018 02; 4(2):110-118. PMID: 29458961; PMCID: PMC5822736.
      Citations: 110     Fields:    Translation:HumansAnimals
    193. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185. PMID: 29487024; PMCID: PMC6173195.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    194. Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137. PMID: 29369779; PMCID: PMC5955724.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    195. Gong J, Pan K, Fakih M, Pal S, Salgia R. Value-based genomics. Oncotarget. 2018 Mar 20; 9(21):15792-15815. PMID: 29644010; PMCID: PMC5884665.
      Citations: 25     Fields:    
    196. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 01 23; 6(1):8. PMID: 29357948; PMCID: PMC5778665.
      Citations: 564     Fields:    Translation:Humans
    197. Mason C, Ellis PG, Lokay K, Barry A, Dickson N, Page R, Polite B, Salgia R, Savin M, Shamah C, Socinski MA. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting. J Clin Pathw. 2018 Jan-Feb; 4(1):49-54. PMID: 31453358; PMCID: PMC6709712.
      Citations: 9     
    198. Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 2017 09 22; 8(37):62817. PMID: 28977992; PMCID: PMC5617552.
      Citations:    Fields:    
    199. Reynolds KL, Bedard PL, Lee SH, Lin CC, Cohen E, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ, Tabernero J, Alsina M, Baselga J. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646. PMID: 28899363; PMCID: PMC5596462.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    200. Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192. PMID: 28835699; PMCID: PMC5569108.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    201. Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. 2017 Sep 19; 8(41):71223-71233. PMID: 29050358; PMCID: PMC5642633.
      Citations: 24     Fields:    
    202. Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget. 2017 Jul 04; 8(27):43733-43751. PMID: 28415827; PMCID: PMC5546437.
      Citations: 12     Fields:    Translation:HumansCells
    203. Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650. PMID: 28978059; PMCID: PMC5620199.
      Citations: 15     Fields:    
    204. Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget. 2017 Jun 27; 8(26):42198-42213. PMID: 28178681; PMCID: PMC5522060.
      Citations: 33     Fields:    Translation:Humans
    205. Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. Eur J Oncol Nurs. 2017 Aug; 29:125-134. PMID: 28720259; PMCID: PMC5539921.
      Citations: 16     Fields:    Translation:Humans
    206. Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2017 09 07; 36(36):5219. PMID: 28628114; PMCID: PMC5596203.
      Citations: 3     Fields:    
    207. Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, Salgia R, Raz DJ. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 2017 08 15; 141(4):766-777. PMID: 28481029; PMCID: PMC5527746.
      Citations: 19     Fields:    Translation:HumansCells
    208. Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 2017 04 18; 8(16):26414-26423. PMID: 28061482; PMCID: PMC5432268.
      Citations: 5     Fields:    
    209. Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2017 08; 36(31):4526. PMID: 28368404; PMCID: PMC5543253.
      Citations: 1     Fields:    
    210. Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565. PMID: 28373408.
      Citations: 73     Fields:    Translation:HumansCells
    211. Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189. PMID: 28427013.
      Citations: 7     Fields:    Translation:Humans
    212. Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncol Lett. 2017 Jun; 13(6):4027-4034. PMID: 28588695; PMCID: PMC5452919.
      Citations: 3     
    213. Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734. PMID: 27244893; PMCID: PMC5386642.
      Citations: 2     Fields:    Translation:Humans
    214. Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, Repollet M, Sanders R, Baeten K, D'Haese D, Spigel DR. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344. PMID: 28299514; PMCID: PMC5418321.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    215. Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496. PMID: 28075524; PMCID: PMC5378278.
      Citations: 17     Fields:    Translation:HumansCells
    216. Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460). PMID: 28049763; PMCID: PMC7094775.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    217. Brooks GA, Bosserman LD, Mambetsariev I, Salgia R. Value-Based Medicine and Integration of Tumor Biology. Am Soc Clin Oncol Educ Book. 2017; 37:833-840. PMID: 28561700.
      Citations: 5     Fields:    Translation:Humans
    218. Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017 03; 105:7-13. PMID: 28236984.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    219. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    220. Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891. PMID: 27602770; PMCID: PMC5341844.
      Citations: 27     Fields:    Translation:HumansCells
    221. Wood K, Hensing T, Salgia R. KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374. PMID: 27442777.
      Citations:    Fields:    Translation:Humans
    222. Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992. PMID: 27623107; PMCID: PMC5021085.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    223. Sattler M, Salgia R. MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3. PMID: 27565402.
      Citations: 3     Fields:    Translation:Humans
    224. Won B, Mambetsariev I, Salgia R. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568. PMID: 27480287; PMCID: PMC4969677.
      Citations:    Fields:    Translation:Humans
    225. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504. PMID: 27450722.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    226. Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86. PMID: 27422810; PMCID: PMC5010956.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    227. Wood K, Hensing T, Malik R, Salgia R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12. PMID: 27100819.
      Citations: 83     Fields:    Translation:Humans
    228. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70. PMID: 27245569; PMCID: PMC4912370.
      Citations: 53     Fields:    Translation:Humans
    229. Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016 07; 16(7):737-49. PMID: 27139190; PMCID: PMC4926789.
      Citations: 12     Fields:    Translation:Humans
    230. Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016 May 24; 7(21):31586-601. PMID: 26980710; PMCID: PMC5058780.
      Citations: 53     Fields:    Translation:HumansCells
    231. Rosell R, Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Shaw AT, Narasimhan NI, Dorer DJ, Kerstein D, Camidge DR. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S114. PMID: 27198273.
      Citations:    
    232. Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578. PMID: 27080907; PMCID: PMC4832330.
      Citations: 25     Fields:    Translation:HumansCells
    233. Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86. PMID: 26934441; PMCID: PMC4951336.
      Citations: 11     Fields:    Translation:Humans
    234. Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33. PMID: 26871945; PMCID: PMC4924666.
      Citations: 26     Fields:    Translation:HumansCells
    235. Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R. The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus. 2016 Mar 16; 8(3):e533. PMID: 27092293; PMCID: PMC4833499.
      Citations: 1     
    236. Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016 Feb 26; 8(2):e513. PMID: 27026837; PMCID: PMC4807912.
      Citations: 14     
    237. Lukas RV, Kumthekar P, Rizvi S, Salgia R. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58. PMID: 26888310.
      Citations: 6     Fields:    Translation:Humans
    238. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. PMID: 26829312; PMCID: PMC4836290.
      Citations: 86     Fields:    Translation:HumansAnimals
    239. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. PMID: 26802155; PMCID: PMC4803455.
      Citations: 45     Fields:    Translation:Humans
    240. Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biol Ther. 2016; 17(1):91-103. PMID: 26574927; PMCID: PMC6093410.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    241. Lovly CM, Salama AK, Salgia R. Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35:e585-93. PMID: 27249771; PMCID: PMC10132823.
      Citations: 21     Fields:    Translation:Humans
    242. Fu P, Usatyuk PV, Jacobson J, Cress AE, Garcia JG, Salgia R, Natarajan V. Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function. Pulm Circ. 2015 Dec; 5(4):619-30. PMID: 26697169; PMCID: PMC4671736.
      Citations: 14     
    243. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. PMID: 26527777; PMCID: PMC4678179.
      Citations: 245     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    244. Salgia R, Sargis RM. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 2015 Oct; 38(5):442-7. PMID: 23934135; PMCID: PMC4055562.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    245. Jen J, Lin LL, Chen HT, Liao SY, Lo FY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2016 05 05; 35(18):2357-69. PMID: 26279304; PMCID: PMC4865475.
      Citations: 25     Fields:    Translation:HumansCells
    246. Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R. Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine. 2015 Nov; 11(8):1971-4. PMID: 26282382; PMCID: PMC5051269.
      Citations: 2     Fields:    Translation:Animals
    247. Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 04; 290(36):21901-14. PMID: 26205821; PMCID: PMC4571945.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    248. Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, Singleton PA. HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. Front Oncol. 2015; 5:164. PMID: 26258071; PMCID: PMC4508840.
      Citations: 17     
    249. Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75. PMID: 26169924; PMCID: PMC4989864.
      Citations: 69     Fields:    Translation:Humans
    250. Lukas RV, Hasan Y, Nicholas MK, Salgia R. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. J Clin Neurosci. 2015 Dec; 22(12):1978-9. PMID: 26159887.
      Citations: 4     Fields:    Translation:Humans
    251. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395.
      Citations: 43     Fields:    Translation:Humans
    252. Nocula-Lugowska M, Lugowski M, Salgia R, Kossiakoff AA. Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin. J Mol Biol. 2015 Jul 31; 427(15):2532-2547. PMID: 26087144; PMCID: PMC4521624.
      Citations: 4     Fields:    Translation:HumansCells
    253. Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641. PMID: 26073592; PMCID: PMC4466581.
      Citations: 12     Fields:    Translation:HumansCells
    254. Salgia R. MET as a drug target. Clin Adv Hematol Oncol. 2015 Jun; 13(6):351-3. PMID: 26352889.
      Citations:    Fields:    Translation:Humans
    255. Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8. PMID: 25997818.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    256. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9. PMID: 25971938.
      Citations: 322     Fields:    Translation:HumansCells
    257. Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9. PMID: 25936471; PMCID: PMC4457565.
      Citations: 9     Fields:    Translation:Humans
    258. Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15; 308(10):L1025-38. PMID: 25795725; PMCID: PMC4437005.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    259. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. PMID: 25767293; PMCID: PMC5032632.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    260. Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93. PMID: 25659177.
      Citations: 6     Fields:    Translation:HumansAnimals
    261. Salgia R. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol. 2015; 11(3):489-500. PMID: 25675128.
      Citations: 7     Fields:    Translation:Humans
    262. Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R, Morgensztern D. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693; PMCID: PMC4346098.
      Citations: 57     Fields:    Translation:Humans
    263. Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015 Feb; 14(2):461-9. PMID: 25504632.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    264. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY, Brägelmann J. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. PMID: 25492084.
      Citations: 167     Fields:    Translation:HumansCells
    265. Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6. PMID: 25391996; PMCID: PMC4278660.
      Citations: 5     Fields:    Translation:Humans
    266. Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242. PMID: 25344208; PMCID: PMC4283113.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    267. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      Citations: 49     Fields:    Translation:Humans
    268. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71. PMID: 25264305; PMCID: PMC4264527.
      Citations: 774     Fields:    Translation:HumansCTClinical Trials
    269. Salgia RJ, Mullan PB, McCurdy H, Sales A, Moseley RH, Su GL. The educational impact of the Specialty Care Access Network-Extension of Community Healthcare Outcomes program. Telemed J E Health. 2014 Nov; 20(11):1004-8. PMID: 25226452.
      Citations: 11     Fields:    Translation:Humans
    270. Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919. PMID: 25221930; PMCID: PMC4164360.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    271. West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014 Sep; 1(2):151-154. PMID: 25541622; PMCID: PMC4274795.
      Citations: 8     
    272. Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus. 2015 Nov-Dec; 28(8):772-81. PMID: 25142531.
      Citations: 8     Fields:    Translation:Humans
    273. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Gill PS, Salgia R, Kimple RJ, Wheeler DL, Toulany M. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64. PMID: 25136066; PMCID: PMC4167493.
      Citations: 102     Fields:    Translation:HumansAnimalsCells
    274. Smieliauskas F, MacMahon H, Salgia R, Shih YC. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. J Med Screen. 2014 Dec; 21(4):207-15. PMID: 25118160; PMCID: PMC4407799.
      Citations: 12     Fields:    Translation:Humans
    275. Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem. 2014 Aug 29; 289(35):24043-58. PMID: 25023279; PMCID: PMC4148838.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    276. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34. PMID: 24958824; PMCID: PMC4105486.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    277. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014 Jul; 113 Suppl 1:i103-8. PMID: 24920011; PMCID: PMC4111280.
      Citations: 59     Fields:    Translation:Humans
    278. Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med. 2014 Jun; 3(3):681-92. PMID: 24711160; PMCID: PMC4101760.
      Citations: 12     Fields:    Translation:HumansCells
    279. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433. PMID: 24722523; PMCID: PMC4039220.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    280. Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577. PMID: 24662916; PMCID: PMC3963855.
      Citations: 81     Fields:    Translation:HumansCells
    281. Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opin Investig Drugs. 2014 May; 23(5):675-92. PMID: 24654596.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    282. Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambronero J, Wary KK, Bindokas V, Dudek SM, Salgia R, Garcia JG, Natarajan V. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem. 2014 May 09; 289(19):13476-91. PMID: 24634221; PMCID: PMC4036355.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    283. Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185. PMID: 24628993; PMCID: PMC3995599.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    284. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68. PMID: 24634415; PMCID: PMC4013210.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    285. Gong J, Wang Z, Polejaeva I, Salgia R, Kao CM, Chen CT, Chen G, Chen L. Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. PLoS One. 2014; 9(3):e90059. PMID: 24594684; PMCID: PMC3942380.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    286. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75. PMID: 24493831.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    287. Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5. PMID: 24386952; PMCID: PMC3893521.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    288. Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol. 2014 Jan; 3(1):61-75. PMID: 25054901; PMCID: PMC6128200.
      Citations: 4     Fields:    Translation:Humans
    289. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117. PMID: 24292963.
      Citations: 56     Fields:    Translation:Humans
    290. Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84. PMID: 24327519; PMCID: PMC4286701.
      Citations: 13     Fields:    Translation:HumansCells
    291. Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95. PMID: 24305878; PMCID: PMC5841456.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    292. Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog. 2013; 12:20. PMID: 24319345; PMCID: PMC3853796.
      Citations: 9     
    293. Salgia R, Sattler M. A new hope for precision medicine. Sci Transl Med. 2013 Oct 23; 5(208):208fs38. PMID: 24154598.
      Citations:    Fields:    Translation:Humans
    294. Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23. PMID: 24041868; PMCID: PMC5839143.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    295. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33. PMID: 23893423.
      Citations: 12     Fields:    Translation:Humans
    296. Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668. PMID: 23844053; PMCID: PMC3699624.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    297. Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci. 2013; 10(8):988-94. PMID: 23801885; PMCID: PMC3691797.
      Citations: 11     Fields:    Translation:HumansCells
    298. Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91. PMID: 23792636; PMCID: PMC3742497.
      Citations: 23     Fields:    Translation:HumansCells
    299. Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269. PMID: 23721559; PMCID: PMC3671960.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    300. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41. PMID: 23628526; PMCID: PMC3679338.
      Citations: 41     Fields:    Translation:HumansCells
    301. Zhao Y, Zhao J, Mialki RK, Wei J, Spannhake EW, Salgia R, Natarajan V. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2013 Jul 01; 305(1):L56-63. PMID: 23624790; PMCID: PMC3726943.
      Citations: 8     Fields:    Translation:HumansCells
    302. Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8. PMID: 23610116; PMCID: PMC3661938.
      Citations: 11     Fields:    Translation:Humans
    303. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77. PMID: 23553849; PMCID: PMC3874465.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    304. Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets. 2013 May; 17(5):481-3. PMID: 23506058; PMCID: PMC3758767.
      Citations: 12     Fields:    Translation:HumansAnimals
    305. Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog. 2013; 12:7. PMID: 23599689; PMCID: PMC3622362.
      Citations: 6     
    306. Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY, Brägelmann J. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
      Citations: 15     Fields:    Translation:HumansCells
    307. Lukas RV, Vigneswaran J, Salgia R. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 2013 Mar-Apr; 99(2):e73-6. PMID: 23748834.
      Citations:    Fields:    Translation:Humans
    308. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96. PMID: 23401458; PMCID: PMC3589702.
      Citations: 85     Fields:    Translation:Humans
    309. Lukas RV, Rezania K, Malec M, Salgia R. Teaching Video NeuroImages: myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. Neurology. 2013 Jan 29; 80(5):e55. PMID: 23359380.
      Citations: 3     Fields:    Translation:Humans
    310. Vokes EE, Salgia R, Karrison TG. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9. PMID: 23251009.
      Citations: 13     Fields:    Translation:Humans
    311. Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem. 2013 Jan 25; 288(4):2191-200. PMID: 23212923; PMCID: PMC3554892.
      Citations: 26     Fields:    Translation:HumansCells
    312. Sadiq AA, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S372-4. PMID: 23160322.
      Citations: 2     Fields:    Translation:HumansCells
    313. Sharma S, Dubinett S, Salgia R. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. Am J Respir Crit Care Med. 2012 Nov 15; 186(10):940-1. PMID: 23155211; PMCID: PMC4249776.
      Citations: 2     Fields:    Translation:HumansCells
    314. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, Kindler HL, Salgia R. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5). PMID: 23103606; PMCID: PMC3488720.
      Citations: 3     Fields:    
    315. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94. PMID: 23100466.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    316. Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther. 2012 Oct 01; 2012(1):7-12. PMID: 24791250; PMCID: PMC4004632.
      Citations: 14     
    317. Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330. PMID: 23028939; PMCID: PMC3444486.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    318. Morales La Madrid A, La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210. PMID: 22968692.
      Citations: 16     Fields:    Translation:HumansCells
    319. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT, Jänne PA. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9. PMID: 22954507; PMCID: PMC3936578.
      Citations: 516     Fields:    Translation:HumansCTClinical Trials
    320. Mollberg NM, Vigneswaran Y, Kindler HL, Warnes C, Salgia R, Husain AN, Vigneswaran WT. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92. PMID: 22921241.
      Citations: 17     Fields:    Translation:Humans
    321. Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):25-32. PMID: 22710038.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    322. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul; 144(1):33-8. PMID: 22710039.
      Citations: 230     Fields:    Translation:HumansPHPublic Health
    323. Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, Salgia R, Wang YC. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer. 2012 Jun 12; 12:235. PMID: 22691236; PMCID: PMC3488578.
      Citations: 28     Fields:    Translation:Humans
    324. Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51. PMID: 22585712.
      Citations: 21     Fields:    Translation:HumansCells
    325. Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65. PMID: 22722787.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    326. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67. PMID: 22343475.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    327. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906. PMID: 22363766; PMCID: PMC3283716.
      Citations: 46     Fields:    Translation:HumansCells
    328. Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012 Feb 28; 106(5):839-45. PMID: 22333598; PMCID: PMC3305978.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    329. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012 May; 26(5):2175-86. PMID: 22321727; PMCID: PMC3336787.
      Citations: 281     Fields:    Translation:HumansAnimalsCells
    330. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81. PMID: 22198429.
      Citations: 37     Fields:    Translation:Humans
    331. Lukas RV, Nicholas MK, Villaflor V, Hoffman PC, Salgia R. Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. J Neurol Res. 2012 Feb 01; 2(1):1-9. PMID: 23504695; PMCID: PMC3596833.
      Citations: 4     
    332. Mollberg NM, Parsad NM, Armato SG, Vigneswaran J, Kindler HL, Sensakovic WF, Salgia R, Silverstein JC, Vigneswaran WT. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70. PMID: 23102002; PMCID: PMC3723194.
      Citations: 1     Fields:    Translation:Humans
    333. Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW, Doçi CL. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol. 2012 Jan; 31(1):15-24. PMID: 22123719; PMCID: PMC3237951.
      Citations: 5     Fields:    Translation:HumansCells
    334. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011 Dec; 11(12):1655-62. PMID: 22047509; PMCID: PMC3258451.
      Citations: 25     Fields:    Translation:HumansAnimals
    335. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011 Dec; 1(7):573-9. PMID: 22389872; PMCID: PMC3289149.
      Citations: 55     Fields:    Translation:HumansCells
    336. Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. PMID: 22100149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    337. Sadiq AA, Geynisman DM, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1810-1. PMID: 22005540.
      Citations: 3     Fields:    Translation:Humans
    338. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10. PMID: 22042947; PMCID: PMC3255989.
      Citations: 209     Fields:    Translation:HumansCTClinical Trials
    339. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    340. Zhao J, He D, Berdyshev E, Zhong M, Salgia R, Morris AJ, Smyth SS, Natarajan V, Zhao Y. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J. 2011 Oct 01; 439(1):45-55. PMID: 21696367; PMCID: PMC3674636.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    341. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38. PMID: 21946983.
      Citations: 140     Fields:    Translation:Humans
    342. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12. PMID: 21933749; PMCID: PMC3328296.
      Citations: 363     Fields:    
    343. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    344. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol. 2011 Jul; 3(4):171-84. PMID: 21904579; PMCID: PMC3150066.
      Citations: 52     
    345. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R, Brägelmann J. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46. PMID: 21543897; PMCID: PMC3149873.
      Citations: 51     Fields:    Translation:HumansCells
    346. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67. PMID: 21712447; PMCID: PMC3156871.
      Citations: 40     Fields:    Translation:HumansCells
    347. Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50. PMID: 21676484.
      Citations: 6     Fields:    Translation:Humans
    348. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Ratain MJ, Salgia R, Müller T. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412; PMCID: PMC3646303.
      Citations: 224     Fields:    Translation:HumansCTClinical Trials
    349. Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50. PMID: 21607942; PMCID: PMC3383858.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    350. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6. PMID: 21623265.
      Citations: 177     Fields:    Translation:Humans
    351. Schweizer MT, Mehta R, Salgia R, Villaflor VM. Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. J Clin Oncol. 2011 Jul 10; 29(20):e598-600. PMID: 21519014.
      Citations: 5     Fields:    Translation:Humans
    352. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. PMID: 21421117.
      Citations: 19     Fields:    Translation:HumansCells
    353. Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr; 6(4):786-9. PMID: 21289521.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    354. Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog. 2011 Mar 03; 10:4. PMID: 21383961; PMCID: PMC3049271.
      Citations: 3     
    355. Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM, Dakin-Haché K. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22. PMID: 21364031; PMCID: PMC3118405.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    356. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. PMID: 21603121; PMCID: PMC3164615.
      Citations: 8     
    357. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011 Sep 01; 117(17):3889-99. PMID: 21858799; PMCID: PMC3160199.
      Citations: 18     Fields:    Translation:Humans
    358. Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94. PMID: 21337123; PMCID: PMC3077059.
      Citations: 9     Fields:    Translation:Humans
    359. Liu W, He L, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ, Ramírez J. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7. PMID: 21292812; PMCID: PMC3070854.
      Citations: 22     Fields:    Translation:Humans
    360. Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Future. 2011 Feb; 36(2):91-99. PMID: 26412935; PMCID: PMC4582997.
      Citations: 3     
    361. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47). PMID: 21304468; PMCID: PMC3182654.
      Citations: 4     Fields:    Translation:Humans
    362. Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54. PMID: 22181983.
      Citations: 11     Fields:    Translation:HumansCells
    363. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67. PMID: 21156980; PMCID: PMC4327979.
      Citations: 100     Fields:    Translation:HumansAnimalsCells
    364. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6. PMID: 21102269.
      Citations: 31     Fields:    Translation:Humans
    365. Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9. PMID: 21072051; PMCID: PMC4078661.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    366. Mackinnon AC, Tretiakova M, Henderson L, Mehta RG, Yan BC, Joseph L, Krausz T, Husain AN, Reid ME, Salgia R. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24. PMID: 21045234; PMCID: PMC3002839.
      Citations: 30     Fields:    Translation:HumansCells
    367. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med. 2010 Nov; 134(11):1702-5. PMID: 21043826; PMCID: PMC3049158.
      Citations: 12     Fields:    Translation:HumansCells
    368. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ, Jänne PA. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703. PMID: 20979469; PMCID: PMC3014291.
      Citations: 1808     Fields:    Translation:HumansCTClinical Trials
    369. Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605. PMID: 20622007; PMCID: PMC2952262.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    370. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20; 28(15):2598-603. PMID: 20385980.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    371. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer. 2010 Apr 01; 116(7):1629-37. PMID: 20151426; PMCID: PMC2847065.
      Citations: 109     Fields:    Translation:HumansCells
    372. Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85. PMID: 20360610; PMCID: PMC2881783.
      Citations: 66     Fields:    Translation:HumansCells
    373. Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A. DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER. Curr Proteomics. 2010 Apr 01; 7(1):49-65. PMID: 20526421; PMCID: PMC2880513.
      Citations: 7     
    374. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010 Mar 15; 9(6):409-16. PMID: 20147779; PMCID: PMC6047303.
      Citations: 35     Fields:    Translation:HumansCells
    375. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010 Feb 19; 2(1):5. PMID: 20298531; PMCID: PMC2831839.
      Citations: 15     
    376. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972. PMID: 20126411; PMCID: PMC2813301.
      Citations: 60     Fields:    Translation:HumansCells
    377. Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):225-37. PMID: 20067553; PMCID: PMC2979310.
      Citations: 26     Fields:    Translation:HumansCells
    378. Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010 Jan-Mar; 4(1):146-52. PMID: 20139696; PMCID: PMC2852571.
      Citations: 33     Fields:    Translation:HumansAnimals
    379. Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010 Mar; 31(6):625-33. PMID: 20003093.
      Citations: 11     Fields:    Translation:Humans
    380. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30. PMID: 19892771.
      Citations: 22     Fields:    Translation:Humans
    381. Faoro L, Cervantes GM, El-Hashani E, Salgia R. MET receptor tyrosine kinase. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1064-5. PMID: 19861919; PMCID: PMC2846396.
      Citations: 5     Fields:    Translation:HumansCells
    382. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47. PMID: 19738072; PMCID: PMC2762355.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    383. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23. PMID: 19723643; PMCID: PMC2767337.
      Citations: 94     Fields:    Translation:Humans
    384. Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 2009 Oct 02; 284(40):27524-32. PMID: 19651775; PMCID: PMC2785681.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    385. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul; 30(1):37-47. PMID: 19392863; PMCID: PMC6871653.
      Citations: 297     Fields:    Translation:Humans
    386. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol. 2009 Apr; 4(4):444-7. PMID: 19333071; PMCID: PMC2664527.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    387. Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S52-8. PMID: 19393836; PMCID: PMC3268697.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    388. Sattler M, Salgia R. The MET axis as a therapeutic target. Update Cancer Ther. 2009 Apr 01; 3(3):109-118. PMID: 20368753; PMCID: PMC2847295.
      Citations: 20     
    389. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31. PMID: 19318576; PMCID: PMC2871252.
      Citations: 122     Fields:    Translation:HumansAnimalsCells
    390. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14. PMID: 19139719; PMCID: PMC2741690.
      Citations: 43     Fields:    Translation:HumansCells
    391. Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. J Carcinog. 2009; 8:15. PMID: 19955662; PMCID: PMC2791827.
      Citations: 1     
    392. Kanteti R, Yala S, Ferguson MK, Salgia R. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98. PMID: 19817696; PMCID: PMC2761881.
      Citations: 18     Fields:    Translation:HumansCells
    393. Song J, Volkov S, Shea CR, Alegre ML, Salgia R, Gregg K, Curran JJ, Woodruff J, Krausz T, Levine JS, Sweiss NJ. Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. J Cutan Pathol. 2009 Oct; 36 Suppl 1:31-4. PMID: 19210585.
      Citations: 7     Fields:    Translation:Humans
    394. Faoro L, Hutto JY, Salgia R, El-Zayaty SA, Ferguson MK, Cheney RT, Reid ME, Armato SG, Krausz T, Husain AN. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8. PMID: 19061284.
      Citations: 8     Fields:    Translation:Humans
    395. Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med. 2008 Dec 01; 2(6):577-586. PMID: 19802373; PMCID: PMC2742385.
      Citations: 20     Fields:    
    396. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37. PMID: 18709663; PMCID: PMC2583960.
      Citations: 129     Fields:    Translation:HumansCells
    397. Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 2009 Jan 29; 28(4):518-33. PMID: 19015641; PMCID: PMC2633425.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    398. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7. PMID: 18990162; PMCID: PMC2741693.
      Citations: 48     Fields:    Translation:HumansCells
    399. Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8. PMID: 18765998; PMCID: PMC2605682.
      Citations: 5     Fields:    Translation:HumansCells
    400. Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19. PMID: 18836658; PMCID: PMC5848684.
      Citations: 9     Fields:    Translation:Humans
    401. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11. PMID: 18758303; PMCID: PMC4535721.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    402. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14. PMID: 18543326.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    403. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79. PMID: 18672314; PMCID: PMC2659375.
      Citations: 47     Fields:    Translation:Humans
    404. Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905. PMID: 18559611.
      Citations: 13     Fields:    Translation:HumansCells
    405. Faoro L, Cohen EE, Govindan R, Kozloff MF, Hoffman PC, Maitland ML, Verel K, Szeto L, Salgia R, Vokes EE. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):19130. PMID: 27947490.
      Citations:    
    406. Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, Rowland KM, Salgia R, Aggarwal N, Gadgeel SM. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. J Clin Oncol. 2008 May 20; 26(15_suppl):8053. PMID: 27948945.
      Citations:    
    407. Maitland ML, Kasza KE, Lacouture ME, Liu W, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Karrison T, Vokes EE. Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8089. PMID: 27948963.
      Citations:    
    408. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol. 2008 May 20; 26(15_suppl):3522. PMID: 27949731.
      Citations:    
    409. Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1104-10. PMID: 18483332; PMCID: PMC2748868.
      Citations: 34     Fields:    Translation:Humans
    410. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF, Chicago Phase II Consortium, PMH Phase II Consortium, California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55. PMID: 18423560; PMCID: PMC2699608.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    411. Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 2008 Jun; 7(6):856-63. PMID: 18340114; PMCID: PMC2580824.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    412. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6. PMID: 18281659; PMCID: PMC3715075.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    413. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42. PMID: 18172305; PMCID: PMC2767335.
      Citations: 66     Fields:    Translation:HumansAnimals
    414. Salgia R. Stamp out lung cancer. J Carcinog. 2008; 7:7. PMID: 19008566; PMCID: PMC2669726.
      Citations:    
    415. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2008; 7:9. PMID: 19240370; PMCID: PMC2669728.
      Citations: 109     
    416. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):976-84. PMID: 18021219.
      Citations: 17     Fields:    Translation:HumansCells
    417. Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42. PMID: 18045058.
      Citations: 3     Fields:    Translation:HumansCells
    418. Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Garcia JG. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007 Oct 19; 282(42):30643-57. PMID: 17702746.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    419. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77. PMID: 17667909; PMCID: PMC2360323.
      Citations: 75     Fields:    Translation:HumansCells
    420. Zhao Y, He D, Stern R, Usatyuk PV, Spannhake EW, Salgia R, Natarajan V. Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal. 2007 Nov; 19(11):2329-38. PMID: 17689924; PMCID: PMC2149844.
      Citations: 17     Fields:    Translation:HumansCells
    421. Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63. PMID: 17551302.
      Citations:    Fields:    Translation:Humans
    422. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58. PMID: 17522864.
      Citations: 22     Fields:    Translation:HumansCells
    423. Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007 May-Jun; 26(3):451-66. PMID: 17407130.
      Citations: 17     Fields:    
    424. Abidoye O, Murukurthy N, Salgia R. Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials. 2007 May; 2(2):143-7. PMID: 18473999.
      Citations: 8     Fields:    Translation:Humans
    425. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34. PMID: 17440059.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    426. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53. PMID: 17404109.
      Citations: 83     Fields:    Translation:HumansCells
    427. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007 Mar; 9(2):102-8. PMID: 17288874.
      Citations: 56     Fields:    Translation:HumansAnimals
    428. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94. PMID: 17322284.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    429. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9. PMID: 17308108.
      Citations: 138     Fields:    Translation:HumansAnimals
    430. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84. PMID: 17311534.
      Citations: 23     Fields:    Translation:Humans
    431. Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60. PMID: 17382025.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    432. Abidoye O, Ferguson MK, Salgia R. Lung carcinoma in African Americans. Nat Clin Pract Oncol. 2007 Feb; 4(2):118-29. PMID: 17259932.
      Citations: 26     Fields:    Translation:HumansPHPublic Health
    433. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22. PMID: 17255273.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    434. Chhatriwala H, Jafri N, Salgia R. A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther. 2006 Dec; 5(12):1600-7. PMID: 17224634.
      Citations: 9     Fields:    Translation:Humans
    435. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70. PMID: 17189397.
      Citations: 80     Fields:    Translation:HumansCells
    436. Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92. PMID: 17052295.
      Citations: 13     Fields:    Translation:Humans
    437. Salgia R. c-Met inhibition. Clin Adv Hematol Oncol. 2006 Nov; 4(11):823-4. PMID: 17143251.
      Citations: 4     Fields:    Translation:Humans
    438. Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, Salgia R. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer. 2006 Nov; 54(2):243-5. PMID: 16949700.
      Citations:    Fields:    Translation:Humans
    439. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61. PMID: 16397249.
      Citations: 73     Fields:    Translation:HumansCells
    440. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006 Jan; 3(1):50-7; quiz 1 p following 57. PMID: 16407879.
      Citations: 35     Fields:    Translation:Humans
    441. Pisick E, Salgia R. Molecular biology of malignant mesothelioma: a review. Hematol Oncol Clin North Am. 2005 Dec; 19(6):997-1023, v. PMID: 16325120.
      Citations: 5     Fields:    Translation:HumansCells
    442. Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Res. 2005 Jun 15; 65(12):5301-9. PMID: 15958577.
      Citations: 15     Fields:    Translation:HumansCells
    443. Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets. 2005 Jun; 9(3):533-59. PMID: 15948672.
      Citations: 8     Fields:    Translation:Humans
    444. Jacobs M, Weber R, Hainsworth J, Schwartzberg L, Strauss J, Tatsuta N, Du Z, McLeod M, Dahl T, Salgia R. A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naïve advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7106. PMID: 27944185.
      Citations:    
    445. Cunningham C, Richards D, Salgia R, Leonard R, Raju R, Arseneau J, Packer S, Gregoire L, Haltom E, Uprichard MJ. Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. J Clin Oncol. 2005 Jun; 23(16_suppl):7120. PMID: 27944217.
      Citations:    
    446. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Obasaju C, Haraf DJ, Salgia R, Vokes EE. A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):7062. PMID: 27944519.
      Citations:    
    447. Rudin CM, Salgia R, Wang XF, Green MR, Vokes EE. CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7168. PMID: 27944986.
      Citations:    
    448. Oxnard GR, Armato SG, Salgia R, Kindler HL. Development of response criteria for mesothelioma based on a mathematical model. J Clin Oncol. 2005 Jun; 23(16_suppl):7176. PMID: 27944992.
      Citations:    
    449. Hahn O, Salgia R. Novel therapies in lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):343-67, vii. PMID: 15833410.
      Citations: 2     Fields:    Translation:Humans
    450. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9. PMID: 15788682.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    451. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88. PMID: 15735036.
      Citations: 248     Fields:    Translation:HumansCells
    452. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004 Dec; 15(6):419-33. PMID: 15561600.
      Citations: 141     Fields:    Translation:HumansCells
    453. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26. PMID: 15922853.
      Citations: 193     Fields:    Translation:HumansAnimals
    454. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23. PMID: 15486067.
      Citations: 101     Fields:    Translation:HumansCells
    455. Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004 Aug 06; 4:589-604. PMID: 15349502; PMCID: PMC5956372.
      Citations: 18     Fields:    Translation:HumansAnimals
    456. Mukhopadhyay NK, Gilchrist D, Gordon GJ, Chen CJ, Bueno R, Lu ML, Salgia R, Sugarbaker DJ, Jaklitsch MT. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Ann Thorac Surg. 2004 Aug; 78(2):450-7. PMID: 15276495.
      Citations: 9     Fields:    Translation:HumansCells
    457. Jafri N, Salgia R. Biology and novel therapeutics for neuroendocrine tumors of the lung. J Biol Regul Homeost Agents. 2004 Jul-Dec; 18(3-4):275-90. PMID: 15786694.
      Citations: 1     Fields:    Translation:Humans
    458. Sattler M, Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leuk Res. 2004 May; 28 Suppl 1:S11-20. PMID: 15036937.
      Citations: 19     Fields:    Translation:HumansCells
    459. Kraeft SK, Ladanyi A, Galiger K, Herlitz A, Sher AC, Bergsrud DE, Even G, Brunelle S, Harris L, Salgia R, Dahl T, Kesterson J, Chen LB. Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res. 2004 May 01; 10(9):3020-8. PMID: 15131038.
      Citations: 21     Fields:    Translation:HumansCells
    460. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar-Apr; 24(2C):1031-8. PMID: 15154618.
      Citations: 34     Fields:    Translation:Humans
    461. Ma PC, Salgia R. Novel targets for therapeutic agents in small cell lung cancer. J Natl Compr Canc Netw. 2004 Mar; 2(2):165-72. PMID: 19777705.
      Citations: 4     Fields:    Translation:HumansCells
    462. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11. PMID: 14981588.
      Citations: 8     Fields:    Translation:Humans
    463. Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res. 2004; 119:121-38. PMID: 15164876.
      Citations: 11     Fields:    Translation:HumansAnimals
    464. Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol. 2004; 23(4):237-51. PMID: 15511212.
      Citations: 5     Fields:    Translation:HumansCells
    465. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7. PMID: 14676110.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    466. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25. PMID: 12884908.
      Citations: 186     Fields:    Translation:HumansCells
    467. Pisick E, Jagadeesh S, Salgia R. Small cell lung cancer: from molecular biology to novel therapeutics. J Exp Ther Oncol. 2003 Nov-Dec; 3(6):305-18. PMID: 14678519.
      Citations: 4     Fields:    Translation:Humans
    468. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81. PMID: 14559814.
      Citations: 201     Fields:    Translation:HumansAnimalsCells
    469. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003 Sep 01; 63(17):5462-9. PMID: 14500382.
      Citations: 84     Fields:    Translation:AnimalsCells
    470. Pisick E, Skarin AT, Salgia R. Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res. 2003 Jul-Aug; 23(4):3379-96. PMID: 12926079.
      Citations: 8     Fields:    Translation:Humans
    471. Brown JR, Wieczorek TJ, Shaffer K, Salgia R. Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8. PMID: 12805344.
      Citations: 4     Fields:    Translation:Humans
    472. Irie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung. J Clin Oncol. 2003 Jun 01; 21(11):2220-2. PMID: 12775751.
      Citations: 1     Fields:    Translation:Humans
    473. Kijima T, Maulik G, Ma PC, Madhiwala P, Schaefer E, Salgia R. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med. 2003 Apr-Jun; 7(2):157-64. PMID: 12927054; PMCID: PMC6740062.
      Citations: 5     Fields:    Translation:HumansCells
    474. Sattler M, Quinnan LR, Pride YB, Gramlich JL, Chu SC, Even GC, Kraeft SK, Chen LB, Salgia R. 2-methoxyestradiol alters cell motility, migration, and adhesion. Blood. 2003 Jul 01; 102(1):289-96. PMID: 12637335.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    475. Salgia R, Skaring AT. p53 and Bcl-2 in small cell-lung cancer. Clin Lung Cancer. 2003 Mar; 4(5):303. PMID: 14609449.
      Citations:    Fields:    
    476. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30. PMID: 12586798.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    477. Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71. PMID: 12635090.
      Citations: 13     Fields:    Translation: